| Oct 30 |
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
|
| Oct 21 |
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 21 |
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 18 |
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 18 |
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 16 |
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
|
| Oct 10 |
bioAffinity Technologies names J. Michael Edwards as CFO
|
| Oct 10 |
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
|
| Oct 9 |
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
|
| Sep 18 |
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
|
